Applications published 26 December 2007

• Methods and compsns for modified release of nutritional supplements
Mannatech 1868448*

• Process for the production of phospholipids
Probio Group 1868449*

• Sustained energy release compsns
Cargill 1868450*

• Hydroxydeoxybenzoins and the use thereof to mask a bitter taste
Symrise 1868452*

• A method for preparing extract for the prevention and treatment of hyperlipidaemia and obesity from the extract of aster spathulifolius aerial part and compsn containing the same
Chung, Se Young 1868453*

• A method and compsn for nutritionally improving glucose control and insulin action
Novartis; Novartis Pharma 1868454*

• Controlled release devices and structural elements for use in their manufacture
Castex Products 1868566*

• Compsns with hydrophilic drugs in a hydrophobic medium
Warner-Lambert 1868567*

• Method for preparing a ginkgo extract having a reduced content of 4’-O-methyl pyridoxine and/or bioflavones
Dr Wilmar Schwabe 1868568*

• Liquid aqueous dosage forms for sub-lingual or nasal applications of active agents with amino groups
Unipack 1868569*

• Methods and systems for operating an aerosol generator
AeroGen 1868570*

• Mitochondriotropic phospholipid vesicles
Northeastern University 1868571*

• Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treating of TNF-alpha effects and flu-like symptoms
Guilford, F Timothy 1868572*

• Method for producing ultrafine submicronic suspensions
PharmaSol 1868573*

• Method for carefully producing ultrafine particle suspensions and ultrafine particles and use thereof
Abbott 1868574*

• Injectable compsns of nanoparticulate immunosuppressive compounds
Elan Pharma International 1868576*

• Lacidipine particles
Dr Reddy’s Laboratories, Inc; Dr Reddy’s Laboratories, Ltd 1868577*

• Nanoparticulate corticosteroid and antihistamine formulations
Elan Pharma International 1868578*

• Pharmaceutical compsn comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
Bayer HealthCare 1868580*

• Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
Evonik Röhm 1868580*

• Pharmaceutical compsns having improved dissolution profiles for poorly soluble drugs
Abbott Laboratories 1868581*

• Nanoparticulate and controlled release compsns comprising cyclosporine
Elan Pharma International 1868582*

• Controlled release compsns comprising a cephalosporin for the treatment of a bacterial infection
Elan Pharma International 1868583*

• Dosage forms of risedronate
Procter & Gamble 1868584*

• Abuse resistant capsules
MW Encap 1868585*

• Anti-inflammatory formulation
AKL Inflammatory 1868586*

• Pharmaceutical formulations comprising fenofibric acid and/or its salts
Abbott Laboratories 1868587*

• Capsules containing seminal material for artificial insemination
Universita’ degli Studi di Milano; Universita’ degli Studi di Pavia 1868588*

• A process for the preparation of poly DL-lactide-co-glycolide nanoparticles having antitubercular drugs encapsulated therein
Lifecare Innovations 1868589*

• Method of increasing testosterone and related steroid concentrations in women
Unimed Pharmaceuticals 1868590*

• Pharmacological, chemical and topical agent enhancement apparatus and method for using the same
VIVI Technologies 1868591*

• Treatment of intestinal conditions by a compound which causes RNA interference
Sylentis 1868592*

• Improved methods of and compsns for the prevention of anxiety, substance abuse and dependence
Hythiam 1868593*

• Ganglionic blocking agents for the treatment of epithelial diseases
Dow Pharmaceutical Sciences 1868594*

• Compounds for the treatment of metabolic disorders
Wellstat Therapeutics Corp 1868595*

• Use of lactobacillus rhamnosus GG in combination with a long-chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
Bristol-Myers Squibb 1868596*

• Therapeutic use of nefopan and analogues thereof
Sosei R&D 1868597*

• A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human
Cardimone Pharma Corp 1868598*

• Antitumour combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
Nerviano Medical Sciences 1868599*

• Spirocyclic cyclohexane derivatives for use in the treatment of substance dependency
Grünenthal 1868600*

• Mitotic kinesin inhibitors
Merck 1868601*

• Pharmacological treatment for sleep apnoea
The Board of Trustees of the University of Illinois 1868602*

• Derivatives of gamma-6,7-dihydro-hhimidazo gamma-1,2-alpha imidazole-3-sulphonyl-azetedine-carboxylic acids, esters and amides and use thereof and anti-inflammatory agents
Boehringer Ingelheim Pharma 1868603*

• Regulation of protein synthesis by inhibition of EIF4E-EIF4G interaction
President and Fellows of Harvard College 1868604*

• Phenyl and pyridyl LTA4H modulators
Janssen Pharmaceutica 1868605*

• Use of the NK03 receptor antagonists for the treatment of nausea and vomiting
Merck Sharp & Dohme 1868606*

• Isoquinoline compounds and methods of use thereof
Inotek Pharmaceuticals 1868607*

• Method for administration of capecitabine
F Hoffmann-La Roche 1868608*

• Prokineticin 1 receptor
Janssen Pharmaceutica 1868609*

• Biocompatible polymer compounds for medicinal formulations
3M Innovative Properties 1868610*

• Novel compounds
Glaxo Group 1868611*

• Novel compounds
Glaxo Group 1868612*

• Polymorphs of 3-o-(3’,3’-dimethyl-succinyl) betulinic acid di-N-methyl-D-glucamine
Panacos Pharmaceuticals 1868613*

• Dosage regimen for the treatment of a traumatic brain injury with progesterone
Emory University 1868614*

• Modulation of telomere length in telomerase positive cells and cancer therapy
Alt Solutions 1868615*

• Inhibitors for extracellular signal-regulated kinase docking
The University of Maryland 1868616*

• Combination of a silicon containing component and a hormone
pSiMedica 1868617*

• Topical compsns comprising several mono- and/or oligosaccharides for treating skin diseases of warm blood hair coated animals
Virbac 1868618*

• Use of macrolides for treating intestinal inflammation
Zambon 1868619*

• Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
Advanced Medical Optics 1868620*

• Inorganic materials for haemostatic modulation and therapeutic wound healing
The Regents of the University of California; Stucky, Galen; Ostomel, Todd; Shi, Qihui; Stoimenov, Peter; Holden, Patricia 1868621*

• Selection and use of lactic acid bacteria for reducing inflammation in mammals
Biogaia 1868622*

• Use of LGG in the manufacture of a medicament for the prevention or treatment of respiratory allergies
Bristol-Myers Squibb 1868623*

• Compsns comprising probiotic and sweetener components
The Iams Company 1868624*

• Improved method for preparing ginkgo extracts having a low content of 4’-O-methyl pyridoxine and/or biflavones
Dr Wilmar Schwabe 1868625*

• Improved method for preparing ginkgo extracts having a reduced content of polycyclic aromatic hydrocarbons
Dr Wilmar Schwabe 1868626*

• Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
Queen Mary and Westfield College 1868627*

• Compounds, compsns and methods for the treatment of poxvirus infections
Chimerix 1868628*

• Therapeutic peptides for the treatment of metastatic cancer
University of Arizona 1868629*

• Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity
Novartis Vaccines and Diagnostics; North China Pharmaceutical Group 1868630*

• Use of compounds inducing the synthesis of SIRT proteins in or for the preparation of a cosmetic or pharmaceutical compsn
Société d’Extraction des Principes Actifs 1868631*

• Dermatological and/or cosmetic compsn containing proteins of the SIRT family
Société d’Extraction des Principes Actifs 1868632*

• Compsns and methods for the inhibition of dishevelled proteins
Enzo Biochem 1868633*

• Compsns and methods for inhibiting G protein signalling
University of Rochester 1868634*

• Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
Bristol-Myers Squibb 1868635*

• Uses of recombinant super-compound interferons
Wei, Guangwen 1868636*

• Mechano growth factor peptides and their use
UCL Business; The Board of Trustees of the University of Illinois 1868637*

• Cross-beta structure on microbial organisms
Crossbeta Biosciences 1868638*

• Methods of applying ionisation radiation for therapy of HIV infection
Albert Einstein College of Medicine of Yeshiva University 1868639*

• Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
Leiden University Medical Centre 1868640*